NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden.
Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system.
Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy.
Company Details
- Employees
- 31
- Founded
- -
- Address
- Visionsgatan 56, Cancer Center Karolinska,sweden
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.neogap.se
- HQ
- Stockholm
Neogap Therapeutics Ab Questions
Neogap Therapeutics Ab's website is https://www.neogap.se
Neogap Therapeutics Ab's LinkedIn profile is https://se.linkedin.com/company/neogap-ab
Neogap Therapeutics Ab has
31 employees.
View email and phone details for 31
employees at Neogap Therapeutics Ab.
Neogap Therapeutics Ab's industry is
Pharmaceutical Manufacturing
Neogap Therapeutics Ab's top competitors are
Elicera Therapeutics Ab,
Biolamina,
Northx Biologics,
Sprint Bioscience,
Kindling Bio,
Nextcell Pharma Ab,
Bioarctic,
Anocca,
Atmp Sweden,
Xbrane Biopharma Ab.
Neogap Therapeutics Ab's categories are Pharmaceutical Manufacturing
Neogap Therapeutics Ab's founding year is 2016
